Currently used drugs for glioblastoma (GBM) treatments are ineffective, primarily due to the
significant challenges posed by strong drug resistance, poor blood-brain barrier (BBB) …

Glioblastoma (GBM), the most aggressive and lethal form of malignant brain tumor, is a
therapeutic challenge due to the drug filtration capabilities of the blood‐brain barrier (BBB) …

Durable glioblastoma multiforme (GBM) management requires long‐term chemotherapy
after surgery to eliminate remaining cancerous tissues. Among chemotherapeutics …

The increasing understanding of ferroptosis has indicated its role and therapeutic potential
in cancer; however, this knowledge has yet to be translated into effective therapies …

Ferroptosis, a unique iron-dependent mode of cell death characterized by lipid peroxide
accumulation, holds significant potential for the treatment of glioblastoma (GBM). However …

Glioma cells hijack developmental transcriptional programs to control cell state. During
neural development, lineage trajectories rely on specialized metabolic pathways. However …

Abstract Near‐infrared‐II (NIR‐II) ferroptosis activators offer promising potentials in in vivo
theranostics of deep tumors, such as glioma. However, most cases are nonvisual iron …

Ferroptosis is a type of regulated cell death that plays an essential role in various brain
diseases, including cranial trauma, neuronal diseases, and brain tumors. It has been …

Glioma is a common primary tumor of the central nervous system (CNS), with glioblastoma
multiforme (GBM) being the most malignant, aggressive, and drug resistant. Most drugs are …

Glioblastoma (GBM) is the most common malignant craniocerebral tumor. The treatment of
this cancer is difficult due to its high heterogeneity and immunosuppressive …